Parexel’s Leanne Larson and Matthew Gordon shared their thoughts on the growing importance of real world evidence (RWE) in clinical research and in regulatory approval. They also discussed how the COVID-19 pandemic has accelerated the adoption of RWE and put a spotlight on how real world data (RWD) sources are curated and used.
Larson and Gordon remark, “RWE is no longer an innovation. It is the “here and now,” central to how the industry and stakeholders need to approach drug development and to ensure that products are best supported throughout their full lifecycle,” adding, “Aligning evidence-generation planning with both the development and commercialization pathways is key to ensuring patients truly have access to innovative therapies, today and in the future.” Read more here.
(Source: Leanne Larson, Matthew Gordon, PharmExec.com, 10/12/21)
